WO2006079014A3 - Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids - Google Patents

Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids Download PDF

Info

Publication number
WO2006079014A3
WO2006079014A3 PCT/US2006/002255 US2006002255W WO2006079014A3 WO 2006079014 A3 WO2006079014 A3 WO 2006079014A3 US 2006002255 W US2006002255 W US 2006002255W WO 2006079014 A3 WO2006079014 A3 WO 2006079014A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
nucleic acids
target cells
topical administration
prolonged exposure
Prior art date
Application number
PCT/US2006/002255
Other languages
French (fr)
Other versions
WO2006079014A2 (en
Inventor
Peter Clarke
Sunil Chada
Kerstin Menander
Robert Sobol
Shuyuan Zhang
Original Assignee
Introgen Therapeutics Inc
Peter Clarke
Sunil Chada
Kerstin Menander
Robert Sobol
Shuyuan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgen Therapeutics Inc, Peter Clarke, Sunil Chada, Kerstin Menander, Robert Sobol, Shuyuan Zhang filed Critical Introgen Therapeutics Inc
Priority to JP2007552332A priority Critical patent/JP2008528508A/en
Priority to CA002595704A priority patent/CA2595704A1/en
Priority to EP06719205A priority patent/EP1838353A2/en
Priority to AU2006206267A priority patent/AU2006206267A1/en
Publication of WO2006079014A2 publication Critical patent/WO2006079014A2/en
Publication of WO2006079014A3 publication Critical patent/WO2006079014A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Abstract

Compositions and methods for preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid comprised in a solid or semi¬ solid formation or in a transdermal or transcutaneous delivery device are disclosed. Also disclosed are compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include an adhesive. Compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid uptake enhancer are also disclosed. Methods of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that involve these therapeutic compositions and devices are also disclosed.
PCT/US2006/002255 2005-01-21 2006-01-20 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids WO2006079014A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007552332A JP2008528508A (en) 2005-01-21 2006-01-20 Topical administration that allows for sustained exposure of target cells to therapeutic and prophylactic nucleic acids
CA002595704A CA2595704A1 (en) 2005-01-21 2006-01-20 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
EP06719205A EP1838353A2 (en) 2005-01-21 2006-01-20 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
AU2006206267A AU2006206267A1 (en) 2005-01-21 2006-01-20 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64582605P 2005-01-21 2005-01-21
US60/645,826 2005-01-21
US69248105P 2005-06-21 2005-06-21
US60/692,481 2005-06-21

Publications (2)

Publication Number Publication Date
WO2006079014A2 WO2006079014A2 (en) 2006-07-27
WO2006079014A3 true WO2006079014A3 (en) 2006-11-09

Family

ID=36579231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002255 WO2006079014A2 (en) 2005-01-21 2006-01-20 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids

Country Status (8)

Country Link
US (1) US20070066552A1 (en)
EP (1) EP1838353A2 (en)
JP (1) JP2008528508A (en)
KR (1) KR20080012825A (en)
AU (1) AU2006206267A1 (en)
CA (1) CA2595704A1 (en)
RU (1) RU2007131689A (en)
WO (1) WO2006079014A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
WO2008109551A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tacstd1 gene expression and uses thereof
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009091812A2 (en) * 2008-01-14 2009-07-23 Surmodics, Inc. Devices and methods for elution of nucleic acid delivery complexes
US20090253184A1 (en) * 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
JP2009203174A (en) * 2008-02-26 2009-09-10 Hokkaido Univ Iontophoresis composition comprising protein-liposome complex
AU2009231598B2 (en) 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
US20090263377A1 (en) * 2008-04-10 2009-10-22 Charles Lin Il-32b-targeted diagnosis and therapy
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2010019574A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs
EP4219708A3 (en) * 2009-07-17 2023-10-11 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
RU2517082C2 (en) * 2009-11-12 2014-05-27 Федеральное Государственное Учреждение Российского научного центра рентгенорадиологии Росмедтехнологий Method of predicting efficiency of immunotherapy basing on estimation of level of expression of cytokine mrnk in kidney cancer tissue
BE1018740A3 (en) * 2010-08-10 2011-07-05 Oystershell Nv COMPOSITION FOR THE TREATMENT OF HUMID EPITHELIAL SURFACES.
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
US8515525B2 (en) * 2011-08-16 2013-08-20 Women's Imaging Solutions Enterprises Llc Skin adhesive agent for mammography procedures
JP6170047B2 (en) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド Apoptosis-targeting nanoparticles
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
JP2015530413A (en) 2012-09-21 2015-10-15 ベデュ−アッド，フランク Improved vaccine compositions and methods of use
WO2014165999A1 (en) 2013-04-12 2014-10-16 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic viral microparticles for promoting stent biofunctionality and wound healing in vertebrate individuals
EP3039147A4 (en) * 2013-08-27 2017-01-25 Mayo Foundation for Medical Education and Research Treating type i and type ii diabetes
WO2015030079A1 (en) * 2013-08-27 2015-03-05 国立大学法人大阪大学 Joined body joined by chemical bonding at material interface, and joining method for joined body
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9962462B2 (en) * 2015-06-11 2018-05-08 Case Western Reserve University Dry spray on hemostatic system
JP6655243B2 (en) * 2015-09-01 2020-02-26 国立大学法人 鹿児島大学 Method for detecting oral precancerous lesions
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US9877990B2 (en) * 2016-04-08 2018-01-30 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
EP3323410A1 (en) 2016-11-22 2018-05-23 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Pharmaceutical parenteral formulation containing carglumic acid
RU2016146594A (en) * 2016-11-28 2018-05-28 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" The treatment for dementia of various etiologies
WO2018157141A1 (en) * 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
EP3768698A4 (en) * 2018-03-19 2022-03-30 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
KR102184684B1 (en) * 2019-07-05 2020-12-02 연세대학교 산학협력단 Composition for preventing or treating hypopigmentation disorders
EP4314028A1 (en) 2021-04-02 2024-02-07 Krystal Biotech, Inc. Viral vectors for cancer therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005853A1 (en) * 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
WO1999041366A1 (en) * 1998-02-12 1999-08-19 The Board Of Trustees Of The Leland Stanford Junior University Introduction of nucleic acid into skin cells by topical application
WO2001042424A2 (en) * 1999-11-29 2001-06-14 The Collaborative Group, Ltd. Sphingolipid-containing cationic liposomes for topical delivery of bioactive material
DE10214260A1 (en) * 2002-03-30 2003-10-23 Wolfgang Richter Liposomal polynucleotide complex for therapeutic or cosmetic use comprises at least two sequences coding for related products that regulate cell growth, division, differentiation, function and/or synthesis capacity
US20050238606A1 (en) * 2004-04-23 2005-10-27 Sujatha Dokka Compositions and methods for topical delivery of oligonucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087350A2 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005853A1 (en) * 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
WO1999041366A1 (en) * 1998-02-12 1999-08-19 The Board Of Trustees Of The Leland Stanford Junior University Introduction of nucleic acid into skin cells by topical application
WO2001042424A2 (en) * 1999-11-29 2001-06-14 The Collaborative Group, Ltd. Sphingolipid-containing cationic liposomes for topical delivery of bioactive material
DE10214260A1 (en) * 2002-03-30 2003-10-23 Wolfgang Richter Liposomal polynucleotide complex for therapeutic or cosmetic use comprises at least two sequences coding for related products that regulate cell growth, division, differentiation, function and/or synthesis capacity
US20050238606A1 (en) * 2004-04-23 2005-10-27 Sujatha Dokka Compositions and methods for topical delivery of oligonucleotides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NIEMIEC S ET AL: "Follicular transgenic expression of human interleukin-1 receptor antagonist protein following topical application of novel liposome plasmid DNA formulations in vivo", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 13, no. 9 SUPPL., 1996, & ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS; SEATTLE, WASHINGTON, USA; OCTOBER 27-31, 1996, pages S385, XP009068095, ISSN: 0724-8741 *
RAGHAVACHARI N ET AL: "TARGETED GENE DELIVERY TO SKIN CELLS IN VIVO: A COMPARATIVE STUDY OF LIPOSOMES AND POLYMERS AS DELIVERY VEHICLES", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 91, no. 3, March 2002 (2002-03-01), pages 615 - 622, XP001077615, ISSN: 0022-3549 *
VALENTA C ET AL: "The use of polymers for dermal and transdermal delivery", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 58, no. 2, September 2004 (2004-09-01), pages 279 - 289, XP004526312, ISSN: 0939-6411 *
YU W H ET AL: "Topical gene delivery to murine skin.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. MAR 1999, vol. 112, no. 3, March 1999 (1999-03-01), pages 370 - 375, XP002388195, ISSN: 0022-202X *

Also Published As

Publication number Publication date
AU2006206267A1 (en) 2006-07-27
RU2007131689A (en) 2009-02-27
CA2595704A1 (en) 2006-07-27
US20070066552A1 (en) 2007-03-22
JP2008528508A (en) 2008-07-31
KR20080012825A (en) 2008-02-12
WO2006079014A2 (en) 2006-07-27
EP1838353A2 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
WO2006079014A3 (en) Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
WO2004060315A3 (en) Stable topical drug delivery compositions
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2008115262A3 (en) Hsp90 inhibitors containing a zinc binding moiety
MY151457A (en) Topical formulation and uses thereof
EP1971308A4 (en) Topical administration carrier composition and therapeutic formulations comprising same
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
WO2007066150A3 (en) Transdermal administration of active agents for systemic effect
WO2010138544A3 (en) Oral care formulations that enhance amount of soluble zinc
WO2006042034A8 (en) Salt and crystalline forms thereof of a drug
WO2007005941A3 (en) Liver targeted conjugates
EP1852114A4 (en) COMPOSITION CONTAINING DIHOMO-(gamma)-LINOLENIC ACID (DGLA) AS THE ACTIVE INGREDIENT
WO2006100489A3 (en) A transdermal topical composition and its uses
WO2007092284A3 (en) Low dose no donor-containing transdermal patch
WO2009106831A3 (en) Pharmaceutical composition comprising naltrexone
WO2001052897A3 (en) Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors
WO2007127163A3 (en) Cns-tumor treatment method and composition
WO2007075255B1 (en) Mastic gum composition for use as a dietary supplement in humans and animals
WO2007017513A3 (en) Formulations for 7-(t-butoxy)iminomethyl camptothecin
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680009226.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2595704

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007552332

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006206267

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006719205

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007131689

Country of ref document: RU

Ref document number: 1020077019150

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006206267

Country of ref document: AU

Date of ref document: 20060120

Kind code of ref document: A